NEW YORK (360Dx) – Accelerate Diagnostics said after the close of the market on Monday that it had closed its previously announced public offering of 2.75 million shares of its common stock at a price of $28.85 per share for gross proceeds of $79.3 million.
The firm originally offered 2.5 million shares.
Accelerate noted that it has granted the underwriters of the offering a 30-day option to purchase up to an additional 412,500 shares of its common stock at the public offering price.
JP Morgan Securities was the lead book-running manager for the offering. William Blair and Piper Jaffray also acted as joint book-running managers. BTIG was the lead manager.
The firm said it anticipates using net proceeds from the offering for general corporate purposes and to fund commercialization efforts.
In early Tuesday morning trading on the Nasdaq, the firm's shares were up a fraction of one percent at $28.30.